Skip to main content
Fig. 4 | Cost Effectiveness and Resource Allocation

Fig. 4

From: Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

Fig. 4

Cost-effectiveness acceptability curves in probabilistic sensitivity analyses of the PEACE study population. (A and B) are the results from the Chinese healthcare perspective, C and D are the results from the Chinese private payer perspective

The dashed line shows the willingness-to-pay threshold of CNY 257094 per quality-adjusted life-year gained. CNY, Chinese yuan; Evo, evolocumab; QALY, quality-adjusted life-year

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us